FMC did the same thing jumped in to protect their investment by dumping the BOD and kicking management out. But this "largest shareholder" buying out the company and taking on the debt amounts to a billion bucks. With all the baggage tied to VVUS, I just did not see it in the cards for them. Is it real? When June 14 comes and goes we will find out.
Many think it is a fake offer intended to provide volume so they can exit out of the stock. The market clearly does not think it is real since the price did not bounce there immediately.
The post was not meant to start any kind of serious conversation, it was just a shocker, that is all.
Just thinking out loud..
Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. It is marketed in generic form as its hydrochloride salt, naltrexone hydrochloride, and marketed under the trade names Revia and Depade.
The main use of naltrexone is for the treatment of alcohol dependence. Naltrexone was approved for the treatment of alcohol dependence in 1994, following publication of the first two randomized, controlled trials in 1992. Since then a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking.[
Bupropion when used for treating obesity over a period of 6 to 12 months, may result in weight loss of 2.7 kg over placebo. This is not much different from the weight loss produced by several other established medications, such as sibutramine, orlistat and amfepramone.
Again these 2 drugs used in combination in Contrave were not designed for weight loss it is a by product. Belviq works better then Bupropion.
JD you just restated everything myself and other longs have been stating for months. So when it comes from you it is gospel but when one of us post it, we don't know what we are talking about. Back on ignore for you.
wonder if that is because no one believes the offer is real or will be accepted.
But according to CNBC they made the offer public today and the LOI and official offer will be delivered by June 13 I think..
I thought the same thing, but the liability that would be out there if they made this buy out offer and then sold out before June 13 and changed their minds about submitting a buyout offer would put them in hot water. Not sure they could legally get away with this.
Well you should probably take time to read my posts then. Never expected Belviq to be a blockbuster in 12 months. VVUS management did not shop this offer, the offer was made public before it ever was sent to management. Clearly it is a large investors attempt to protect their investment. Second time this has happened in the history of this company. FMC kicked out the last management team and BOD. Now we have new shareholder flexing their muscle.
Again, don't read more into the post. I was just amazed that VVUS got a buy out offer, period. They company is burning 200 million a year. Qsymia has stalled and is going nowhere. Stendra while sales are increasing it is not enough offset the burn rate. VVUS has yet to start the Phase IV studies required as a condition for marketing approval for Qsymia. So with all this negative stuff going on, it is shocking they get an offer. That was all the post stated. I clearly don't see the value in VVUS as a whole and don't forget to add in all the debt and off balance sheet debt.
Aspen investment fund, the largest shareholder. Must be trying to protect what is left of their investment.
This was an offer made public before they even sent it over to management. They should have the offer first part of June. So we can't assume it was done with management consent.
I can honestly say I never thought that would happen... Another day in Bizzaro world.
6.20 a share? All those at a higher price will be waiting a very very long time to get back to break even. Offer coming in June...
Did you miss the above statement, Contrave has the worst tolerability profile among the three drugs? Did you miss that Belviq is a single agent designed to stop cravings and make a person feel full. Both Qsyima and Contrave are combo drugs, i.e. use 2 different drugs and are relying on the side effects of those drugs... Real world weight loss for Belviq is off the charts...
Almost one year on the market and not one single major side effect that was not already documented when 8,000 clinical patients took the drug. Even FDA stated what more can Arena do to prove the drug is safe, 20,000 echos and 8,000 patients were studied... Many more then normal clinical studies are required to do and that is why more issues pop up in the future. Their study groups were too small and did not have a wide enough net to cast.
You have been bashing for 2 years not hyping it. Do you think people can't read or look up your history? What a dork.
We have been outperforming Qsymia for 18 weeks in a row... You think the market wants to be honest about that? You think bears and bloggers want to be honest about that? Not one serious blogger or media outlet has picked up on the trend that Belviq has been outperforming its competition and the overall obesity market for almost 5 months. That fact has been ignored because that is not the talking points they want. They don't want investors leaving VVUS and OREX to run after ARNA. That would be a disaster for some Wall Street insiders that still have not gotten out of their Buy VVUS and Short ARNA trades.